Search Result
Results for "
breast cancer and liver cancer
" in MedChemExpress (MCE) Product Catalog:
2
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-19671
-
SR-45023A; SR 9223i; SK&F-99085
|
Apoptosis
|
Cancer
|
Apomine (SR-45023A) is an antineoplastic agent that inhibits the mevalonate/isoprenoid pathway in cholesterol synthesis.
Apomine can accelerate the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR). Apomine can also inhibit the growth of various types of cancer cells, including lung cancer, colon cancer, breast cancer, and skin cancer. In addition, Apomine is able to induce apoptosis in tumor cell lines derived from leukemia, colon cancer, liver cancer, ovarian cancer, and breast cancer .
|
-
-
- HY-N0563
-
|
AMPK
VEGFR
PI3K
Akt
NF-κB
Cytochrome P450
|
Cardiovascular Disease
Cancer
|
Alizarin is a natural dye. Alizarin can be extracted from the roots of madder plant. Alizarin activates AMPK and VEGFR2/eNOS pathway. Alizarin regulates PI3K/Akt and inhibits NF-κB pathway. Alizarin enhances CYP1A1 enzyme activity. Alizarin has protective effects on hypertension and vascular endothelial dysfunction. Alizarin has anti-tumor activity against multiple cancers including pancreatic cancer, breast cancer, osteosarcoma and liver cancer. Alizarin has been widely used as a pigment in textile fabrics and paintings .
|
-
-
- HY-128553
-
-
-
- HY-N15577
-
|
Drug Derivative
|
Cancer
|
Antiproliferative agent-69 (Compound 1) is a prenylated kaempferol derivative found in the fresh bud’s fur of Platanus acerifolia. Antiproliferative agent-69 shows significant antiproliferative effects against human breast cancer cells (MCF-7) and human hepatocellular carcinoma cells (Hep-G2) with IC50 values of 38.2 μM and 39.5 μM, respectively. Antiproliferative agent-69 is promising for research of breast cancer and liver cancer .
|
-
-
- HY-149085A
-
|
RAR/RXR
|
Cancer
|
(E)-XS-060 is an isomer of XS-060. XS-060 is a RXRα antagonist. XS-060 inhibits pRXRα-PLK1 interaction. XS-060 induces RXRα-dependent mitotic arrest. XS-060 exhibits good antitumor activity against breast cancer, lung adenocarcinoma, and liver cancer .
|
-
-
- HY-158251
-
|
Others
|
Cancer
|
BIBD-300 is a PARP-1 imaging agent with high affinity for PARP-1. BIBD-300 can accurately localize C6 and U87MG tumors, which can be used for research in the diagnosis of breast cancer, prostate cancer, glioma, and liver cancer .
|
-
-
- HY-170648
-
|
Thymidylate Synthase
Apoptosis
PI3K
STAT
Bcl-2 Family
|
Cancer
|
TS-IN-5 (Compound 15) is a thymidylate synthase (TS) inhibitor. TS-IN-5 induces Apoptosis by modulating Bax, BCL-2, PI3K, and STAT1 proteins. TS-IN-5 shows antitumor effects against liver, breast and colon cancers .
|
-
-
- HY-160049
-
|
Nucleoside Antimetabolite/Analog
Biochemical Assay Reagents
|
Cancer
|
BC15 aptamer sodium is an ssDNA aptamer targeting the intracellular protein hnRNP A1, which is highly expressed in cancerous liver tissue. BC15 aptamer sodium specifically recognizes breast cancer cells and can be used to detect cancer cells in other pathological types of breast cancer tissue .
|
-
-
- HY-151570
-
|
Others
|
Cancer
|
Anticancer agent 87 is a potent anticancer agent. Anticancer agent 87 can be used in the research of breast adenocarcinoma and liver cancer .
|
-
-
- HY-151572
-
|
Others
|
Cancer
|
Anticancer agent 88 is a potent anticancer agent. Anticancer agent 88 can be used in the research of breast adenocarcinoma and liver cancer .
|
-
-
- HY-N13213
-
|
Others
|
Cancer
|
Fenugreek Seed Extract is a fenugreek extract. Fenugreek Seed Extract has potential antibacterial and anticancer activities, can inhibit Staphylococcus aureus and Pseudomonas aeruginosa, and inhibit the proliferation of MCF-7 breast cancer cells (no significant effect on liver cancer cells). .
|
-
-
- HY-N3210
-
|
Others
|
Cancer
|
Nb-Demethylechitamine is an alkaloid isolated from the methanol extract of Alstonia rostrata twigs. Nb-Demethylechitamine has in vitro cytotoxic activity against several human cancer cell lines, including human myeloid leukemia HL-60, liver cancer SMMC-7721, lung cancer A-549, breast cancer MCF-7, and colon cancer SW480 cells .
|
-
-
- HY-117047
-
|
Apoptosis
Caspase
|
Cancer
|
ALC67 is a cytotoxic thiazolidine compound with an IC50 of approximately 5 μM against liver, breast cancer, colon cancer, and endometrial cancer cell lines. ALC67 induces apoptosis in cancer cells by activating caspase-9 and causing cell cycle arrest at the SubG1/G1 phase, via a pathway that is independent of death receptors. ALC67 can be used in cancer research .
|
-
-
- HY-108315
-
6-Chrysenamine
|
Others
|
Inflammation/Immunology
Cancer
|
6-Aminochrysene (6-Aminochrysene) is an aromatic amine used as a chemotherapeutic agent in the treatment of splenomegaly, myeloid leukemia, and breast cancer. 6-Aminochrysene is activated by CYP450 in rat liver .
|
-
-
- HY-163938
-
|
PROTACs
|
Cancer
|
PROTAC erf3a Degrader-1 (Compound C63) is an orally active PROTAC erf3a Degrader. PROTAC erf3a Degrader-1 inhibits cancer cell proliferation (eg: 22Rv1). PROTAC erf3a Degrader-1 can be used for research of prostate cancer, ovarian cancer, liver cancer, cervical cancer, leukemia, breast cancer. (Red: erf3a ligand (HY-13778); Black: linker (HY-163960); Blue: CRBN ligand (HY-41547)) .
|
-
-
- HY-172172
-
|
Thymidylate Synthase
Apoptosis
|
Cancer
|
TS-IN-6 (Compound 10) is a thymidylate synthase (TS) inhibitor with an IC50 value of 0.54 μM, demonstrating significant antiproliferative activity. TS-IN-6 induces G1 phase cell cycle arrest and apoptosis (marked by substantial increases in both early and late apoptotic rates) and shows potential for research on cancers such as colon, breast, and liver cancers .
|
-
-
- HY-116494
-
|
BCRP
|
Cancer
|
ML753286 is an orally active and selective BCRP (Breast cancer resistance protein) inhibitor with an IC50 of 0.6 μM. ML753286 has high permeability and low to medium clearance in rodent and human liver S9 fractions, and is stable in plasma cross species .
|
-
-
- HY-173150
-
|
YAP
|
Cancer
|
YAP-IN-1 (Compound (+)-1) is an autophagy (Autophagy) inhibitor targeting YAP1. YAP-IN-1 binds to the Hippo pathway transcription factor YAP1 with a Kd of 9.13 μM and induces its degradation via the chaperone-mediated autophagy (CMA) pathway. This process inhibits Rab7-mediated fusion of autophagosomes and lysosomes, thereby reducing overall autophagy levels without affecting lysosomal function. YAP-IN-1 holds promise for research in cancer (e.g., liver cancer, breast cancer, etc.) .
|
-
-
- HY-N3405
-
|
Glycosidase
Bcl-2 Family
Apoptosis
TGF-β Receptor
NF-κB
Fungal
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
Lariciresinol is an orally active ingredient. Lariciresinol can be isolated from Arabidopsis thaliana. Lariciresinol inhibits α-glucosidase activity (IC50 of 6.97 μM; Ki of 0.046 μM). Lariciresinol dereases Bcl-2, upregulates Bax and induces Apoptosis. Lariciresinol regulates TGF-β and NF-κB pathways. Lariciresinol has antitumor activity against liver cancer, gastric cancer, and breast cancer. Lariciresinol shows antifungal activity and anti-diabetic activity .
|
-
-
- HY-18959
-
|
β-catenin
Wnt
|
Cancer
|
CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of breast and liver cancer stem cells (CSCs) .
|
-
-
- HY-173492
-
|
EGFR
Apoptosis
|
Cancer
|
EGFR-IN-156 (Compound 7f) is an EGFR inhibitor that also has inhibitory activity against mutations EGFRL858R and EGFRT790M (IC50 values are 0.186, 0.131, and 0.107 μM, respectively). EGFR-IN-156 has significant anticancer activity against human cancer cell lines HepG-29 (liver cancer), MCF-7 (breast cancer), and HCT-116 (colon cancer) (IC50 values are 1.67, 5.32, and 6.56 μM, respectively). EGFR-IN-156 inhibits cancer cell proliferation by inducing cell cycle arrest at the G/G1 phase and triggering apoptosis. EGFR-IN-156 shows promise in EGFR-related cancers .
|
-
-
- HY-163938A
-
|
PROTACs
|
Cancer
|
PROTAC erf3a Degrader-2 (Compound C59) is an orally active PROTAC erf3a Degrader. PROTAC erf3a Degrader-2 inhibits protein expression of SRD5A3 and GSPT1(eRF3a). PROTAC erf3a Degrader-2 inhibits cancer cell proliferation (eg: 22Rv1). PROTAC erf3a Degrader-2 can be used for research of prostate cancer, ovarian cancer, liver cancer, cervical cancer, leukemia, breast cancer. (Red: erf3a ligand (HY-13778); Black: linker (HY-163960); Blue: E3 ligase ligand (HY-W763812)) .
|
-
-
- HY-110329
-
|
Others
|
Cancer
|
ML179 (SR-1309) is a inverse LRH1/NR5A2 (Liver receptor homologue-1) agonist with IC50 of 320 nM. ML179 shows anti-proliferation activity in MDA-MB-231 cells. ML179 has the potential for the research of ER-negative breast cancer .
|
-
-
- HY-163747
-
|
VEGFR
|
Cancer
|
VEGFR-2-IN-47 (compound 7g) is a potent VEGFR-2 inhibitor with an IC50 value of 0.072 µM. VEGFR-2-IN-47 can induce G2 / M phase cell cycle arrest, promote apoptosis, and boost immunomodulation by downregulating TNF-α expression and upregulating IL-2 levels in MCF-7 cells. VEGFR-2-IN-47 has the potential to be used for the research of cancer such as breast cancer and liver carcinoma .
|
-
-
- HY-121983
-
|
Phospholipase
|
Cancer
|
CAY10594 is a potent phospholipase D2 (PLD2) inhibitor both in vitro (IC50=140 nM) and in cells (IC50=110 nM) . CAY10594 strongly inhibits the invasive migration of breast cancer cells in vitro and ameliorates acetaminophen-induced acute liver injury by regulating the phosphorylated-GSK-3β/JNK axis .
|
-
-
- HY-116494A
-
|
BCRP
|
Cancer
|
(6R)-ML753286 is an isomer of ML753286 (HY-116494). ML753286 is an orally active and selective BCRP (Breast cancer resistance protein) inhibitor with an IC50 of 0.6 μM. ML753286 has high permeability and low to medium clearance in rodent and human liver S9 fractions, and is stable in plasma cross species .
|
-
-
- HY-N3626
-
|
Others
|
Cancer
|
Coronalolide is a natural triterpene with anticancer effects. Coronalolide exhibits a broad cytotoxic activity for human breast (BT474), gastric (KATO-3), lung (CHAGO), colon (SW-620), and liver (Hep-G2) cancer cell lines, with IC50 values of 6.59 µg/mL, 5.85 µg/mL, 5.42 µg/mL, 4.98 µg/mL, and 6.41 µg/mL, respectively .
|
-
-
- HY-W009538
-
5-Fluoro-5'-deoxycytidine
|
Nucleoside Antimetabolite/Analog
DNA/RNA Synthesis
Drug Metabolite
|
Cancer
|
5'-Deoxy-5-fluorocytidine (5-Fluoro-5'-deoxycytidine) is a cytidine analog and metabolite of Capecitabine (HY-B0016). 5'-Deoxy-5-fluorocytidine is converted from Capecitabine by carboxylesterase in the liver. 5'-Deoxy-5-fluorocytidine is deaminated by cytidine deaminase to generate 5'-deoxy-5-fluorouridine, which is finally converted into 5-fluorouracil (HY-90006) by thymidine phosphorylase in tumor tissues to exert anti-tumor effects. 5'-Deoxy-5-fluorocytidine is used in the researches for solid tumors such as colorectal cancer, non-small cell lung cancer and breast cancer .
|
-
-
- HY-172891
-
|
CDK
HDAC
Apoptosis
|
Cancer
|
CDK9/HDAC1/HDAC3-IN-1 is dual-functional inhibitor of CDK9 and HDAC. CDK9/HDAC1/HDAC3-IN-1 inhibits the protein activity of CDK9/HDAC/HDAC3 with IC50 s of 0.17 μM, 1.73 μM and 1.11 μM for CDK9, HDAC1, and HDAC3, respectively. CDK9/HDAC1/HDAC3-IN-1 inhibits cancer cells by inducing cell apoptosis and cell cycle arrest in the G2/M phase, as well as tumor growth in a murine TNBC MDA-MB-231 xenograft model. CDK9/HDAC1/HDAC3-IN-1 has a broad-spectrum anti-cancer activity, such as breast cancer, cervical cancer, and liver cancer .
|
-
-
- HY-N0401A
-
|
Bacterial
Estrogen Receptor/ERR
FATP
|
Infection
Metabolic Disease
|
(Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6 . (Z)-Ligustilide is orally active, it inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) . (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer .
|
-
-
- HY-108016
-
Encordin
|
Src
PI3K
JNK
STAT
EGFR
Apoptosis
Autophagy
|
Cancer
|
Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib .
|
-
-
- HY-W009538R
-
5-Fluoro-5'-deoxycytidine (Standard)
|
Nucleoside Antimetabolite/Analog
Reference Standards
DNA/RNA Synthesis
Drug Metabolite
|
Cancer
|
5'-Deoxy-5-fluorocytidine (Standard) is the analytical standard of 5'-Deoxy-5-fluorocytidine (HY-W009538). This product is intended for research and analytical applications. 5'-Deoxy-5-fluorocytidine (5-Fluoro-5'-deoxycytidine) is a cytidine analog and metabolite of Capecitabine (HY-B0016). 5'-Deoxy-5-fluorocytidine is converted from Capecitabine by carboxylesterase in the liver. 5'-Deoxy-5-fluorocytidine is deaminated by cytidine deaminase to generate 5'-deoxy-5-fluorouridine, which is finally converted into 5-fluorouracil (HY-90006) by thymidine phosphorylase in tumor tissues to exert anti-tumor effects. 5'-Deoxy-5-fluorocytidine is used in the researches for solid tumors such as colorectal cancer, non-small cell lung cancer and breast cancer .
|
-
-
- HY-W009538S
-
5-Fluoro-5'-deoxycytidine-d3
|
Nucleoside Antimetabolite/Analog
Isotope-Labeled Compounds
DNA/RNA Synthesis
Drug Metabolite
|
Cancer
|
5'-Deoxy-5-fluorocytidine-d3 is deuterated labeled 5'-Deoxy-5-fluorocytidine (HY-W009538). 5'-Deoxy-5-fluorocytidine (5-Fluoro-5'-deoxycytidine) is a cytidine analog and metabolite of Capecitabine (HY-B0016). 5'-Deoxy-5-fluorocytidine is converted from Capecitabine by carboxylesterase in the liver. 5'-Deoxy-5-fluorocytidine is deaminated by cytidine deaminase to generate 5'-deoxy-5-fluorouridine, which is finally converted into 5-fluorouracil (HY-90006) by thymidine phosphorylase in tumor tissues to exert anti-tumor effects. 5'-Deoxy-5-fluorocytidine is used in the researches for solid tumors such as colorectal cancer, non-small cell lung cancer and breast cancer .
|
-
-
- HY-W009538S1
-
5-Fluoro-5'-deoxycytidine-13C5
|
Isotope-Labeled Compounds
DNA/RNA Synthesis
Drug Metabolite
|
Cancer
|
5'-Deoxy-5-fluorocytidine-13C5 is the 13C labeled isotope of 5'-Deoxy-5-fluorocytidine (HY-W009538). 5'-Deoxy-5-fluorocytidine (5-Fluoro-5'-deoxycytidine) is a cytidine analog and metabolite of Capecitabine (HY-B0016). 5'-Deoxy-5-fluorocytidine is converted from Capecitabine by carboxylesterase in the liver. 5'-Deoxy-5-fluorocytidine is deaminated by cytidine deaminase to generate 5'-deoxy-5-fluorouridine, which is finally converted into 5-fluorouracil (HY-90006) by thymidine phosphorylase in tumor tissues to exert anti-tumor effects. 5'-Deoxy-5-fluorocytidine is used in the researches for solid tumors such as colorectal cancer, non-small cell lung cancer and breast cancer .
|
-
-
- HY-N3021
-
|
Endogenous Metabolite
NF-κB
TNF Receptor
FOXO
Microtubule/Tubulin
|
Metabolic Disease
|
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .
|
-
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N0563
-
-
-
- HY-128553
-
-
-
- HY-N3405
-
-
-
- HY-N0401A
-
-
-
- HY-108016
-
-
-
- HY-N3021
-
|
Structural Classification
Natural Products
Classification of Application Fields
Source classification
Metabolic Disease
Endogenous metabolite
Disease Research Fields
|
Endogenous Metabolite
NF-κB
TNF Receptor
FOXO
Microtubule/Tubulin
|
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .
|
-
-
- HY-N15577
-
-
-
- HY-N3210
-
-
-
- HY-N3626
-
|
Triterpenes
Structural Classification
Terpenoids
Source classification
Rubiaceae
Gardenia sootepensis hutchins.
Plants
|
Others
|
Coronalolide is a natural triterpene with anticancer effects. Coronalolide exhibits a broad cytotoxic activity for human breast (BT474), gastric (KATO-3), lung (CHAGO), colon (SW-620), and liver (Hep-G2) cancer cell lines, with IC50 values of 6.59 µg/mL, 5.85 µg/mL, 5.42 µg/mL, 4.98 µg/mL, and 6.41 µg/mL, respectively .
|
-
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-W009538S
-
|
5'-Deoxy-5-fluorocytidine-d3 is deuterated labeled 5'-Deoxy-5-fluorocytidine (HY-W009538). 5'-Deoxy-5-fluorocytidine (5-Fluoro-5'-deoxycytidine) is a cytidine analog and metabolite of Capecitabine (HY-B0016). 5'-Deoxy-5-fluorocytidine is converted from Capecitabine by carboxylesterase in the liver. 5'-Deoxy-5-fluorocytidine is deaminated by cytidine deaminase to generate 5'-deoxy-5-fluorouridine, which is finally converted into 5-fluorouracil (HY-90006) by thymidine phosphorylase in tumor tissues to exert anti-tumor effects. 5'-Deoxy-5-fluorocytidine is used in the researches for solid tumors such as colorectal cancer, non-small cell lung cancer and breast cancer .
|
-
-
- HY-W009538S1
-
|
5'-Deoxy-5-fluorocytidine-13C5 is the 13C labeled isotope of 5'-Deoxy-5-fluorocytidine (HY-W009538). 5'-Deoxy-5-fluorocytidine (5-Fluoro-5'-deoxycytidine) is a cytidine analog and metabolite of Capecitabine (HY-B0016). 5'-Deoxy-5-fluorocytidine is converted from Capecitabine by carboxylesterase in the liver. 5'-Deoxy-5-fluorocytidine is deaminated by cytidine deaminase to generate 5'-deoxy-5-fluorouridine, which is finally converted into 5-fluorouracil (HY-90006) by thymidine phosphorylase in tumor tissues to exert anti-tumor effects. 5'-Deoxy-5-fluorocytidine is used in the researches for solid tumors such as colorectal cancer, non-small cell lung cancer and breast cancer .
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-160049
-
|
|
Aptamers
|
BC15 aptamer sodium is an ssDNA aptamer targeting the intracellular protein hnRNP A1, which is highly expressed in cancerous liver tissue. BC15 aptamer sodium specifically recognizes breast cancer cells and can be used to detect cancer cells in other pathological types of breast cancer tissue .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: